Shire’s (SHP) Hold Rating Reiterated at Liberum Capital

Shire (LON:SHP)‘s stock had its “hold” rating reaffirmed by stock analysts at Liberum Capital in a report issued on Wednesday. They currently have a GBX 4,000 ($55.26) price objective on the biopharmaceutical company’s stock. Liberum Capital’s price objective points to a potential upside of 28.63% from the stock’s previous close.

Other analysts have also issued reports about the company. Shore Capital reissued a “buy” rating on shares of Shire in a report on Monday, November 13th. Berenberg Bank upped their target price on Shire from GBX 5,900 ($81.51) to GBX 6,000 ($82.90) and gave the company a “buy” rating in a report on Monday, November 6th. Kepler Capital Markets reaffirmed a “buy” rating and set a GBX 4,600 ($63.55) target price on shares of Shire in a report on Wednesday, November 1st. Deutsche Bank lowered their target price on Shire from GBX 5,700 ($78.75) to GBX 5,500 ($75.99) and set a “buy” rating for the company in a report on Wednesday, November 1st. Finally, Citigroup reaffirmed a “buy” rating and set a GBX 5,500 ($75.99) target price on shares of Shire in a report on Monday, October 30th. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of GBX 5,238.89 ($72.38).

Shares of Shire (LON:SHP) traded down GBX 71.38 ($0.99) during trading on Wednesday, reaching GBX 3,109.62 ($42.96). The company had a trading volume of 5,230,000 shares, compared to its average volume of 2,920,000. The company has a market capitalization of $28,180.00 and a price-to-earnings ratio of 2,429.39. Shire has a 1 year low of GBX 3,034 ($41.92) and a 1 year high of GBX 5,067 ($70.01).

In other Shire news, insider Dominic Blakemore acquired 165 shares of Shire stock in a transaction dated Tuesday, December 19th. The stock was acquired at an average cost of GBX 3,790 ($52.36) per share, for a total transaction of £6,253.50 ($8,639.82).

COPYRIGHT VIOLATION WARNING: “Shire’s (SHP) Hold Rating Reiterated at Liberum Capital” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/02/14/shires-shp-hold-rating-reiterated-at-liberum-capital.html.

About Shire

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire (LON:SHP)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply